Contrasting fortunes for Roche and AZ in a week of drama.
FDA to make decision on wider lung cancer use within a week.
AZ hopes for blockbuster sales from Imfinzi.
BI developing combinations with its own checkpoint inhibitors
Kite completes filing a day after rival Novartis.
MSD keeps pressure on BMS with EU classical Hodgkin lymphoma indication.